hero image
Dr. Malcolm Moore - University Health Network. Toronto, ON, CA

Dr. Malcolm Moore Dr. Malcolm Moore

Chief, Medical Oncology, Princess Margaret Cancer Centre | University Health Network

Toronto, ON, CANADA

World-class care, research and treatment for patients with Pancreatic Cancer

Media

Publications:

Documents:

Videos:

Dr. Malcolm Moore Believes It

Audio:

Social

Biography

Dr. Moore is director of the Bras Family Drug Development Program at Ontario Cancer Institute/Princess Margaret Hospital. This program was selected by the NIH as one of seven north American sites to perform new drug development of novel anti-cancer agents. This has lead to a major expansion of both the laboratory and clinical components of the drug development program.

Areas of focus for new drug development are signal transduction inhibitors, modulation of gene expression and angiogenesis.

Industry Expertise (4)

Health and Wellness Research Health Care - Services Health Care - Providers

Areas of Expertise (6)

Medical Oncology Chemotherapy Drug Development Pancreatic Cancer Translational Research Prostate Cancer

Education (2)

University of Waterloo: Bachelor of Mathematics, Mathematics and Computer Science 1975

The University of Western Ontario: Doctor of Medicine (M.D.), Medicine 1980

Affiliations (3)

  • Ho Chair in Prostate Cancer Research, Princess Margaret Hospital
  • Chair of the National Cancer Institute of Canada GI cancer disease site
  • Professor, Department of Medicine and Pharmacology, University of Toronto

Articles (5)

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study PubMed.gov

2014-09-01

This phase II, open-label, randomised study evaluated whether patients with metastatic pancreatic cancer receiving erlotinib/gemcitabine derived survival benefits from increasing the erlotinib dose.

view more

Prospective Evaluation of Acute Toxicity and Quality of Life After IMRT and Concurrent Chemotherapy for Anal Canal and Perianal Cancer PubMed.gov

2013-11-01

A prospective cohort study was conducted to evaluate toxicity, quality of life (QOL), and clinical outcomes in patients treated with intensity modulated radiation therapy (IMRT) and concurrent chemotherapy for anal and perianal cancer.

view more

Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance PubMed.gov

2014-08-01

To evaluate the performance of active surveillance as a management strategy in broad populations and to inform the development of surveillance schedules by individual patient data regarding timing and type of relapse.

view more

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers PubMed.gov

2014-09-01

The BRCA1/2 proteins are involved in regulation of cellular proliferation by DNA damage repair via homologous recombination. Therefore, BRCA1/2 mutation carriers with pancreatic cancer may have distinct biologic outcomes.

view more

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer PubMed.gov

2014-09-01

Tremelimumab (CP-675,206) is a fully human monoclonal antibody binding to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) on T cells that stimulates the immune system by blocking the CTLA4-negative regulatory signal. Combination with standard chemotherapy may strengthen antitumor therapy. This is a phase Ib, multisite, open-label, nonrandomized dose escalation trial evaluating the safety, tolerability, and maximum tolerated dose (MTD) of tremelimumab combined with gemcitabine in patients with metastatic pancreatic cancer.

view more

Contact